Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China.
elective nodal irradiation
esophageal cancer
involved-field irradiation
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
22
03
2020
revised:
22
06
2020
accepted:
08
07
2020
pubmed:
26
8
2020
medline:
20
5
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
This study's initial results revealed significant decreases in treatment-related esophagitis and pneumonitis cases in patients with thoracic esophageal squamous cell carcinoma (ESCC) treated with involved-field irradiation (IFI), compared to elective nodal irradiation (ENI). This report outlines the long-term trial results, specifically; overall survival (OS), progression-free survival (PFS), metastasis-free survival (MFS), and locoregional progression-free survival (LRFS). Stage II-III thoracic ESCC patients were assigned randomly, in a 1:1 ratio, into either the ENI or IFI arm. Radiation therapy was delivered once a day in 1.8-2.0 Gy fractions to a total dose of 60.0-66.0 Gy to the gross tumor volume and 50.0-54.0 Gy to the clinical target volume. The primary endpoints were acute treatment-related esophagitis and pneumonitis. The results for the primary endpoints were previously published in 2018. In this article, we analyzed the secondary endpoints including PFS, LRFS, MFS, and OS. Between April 2012 and October 2016, 228 patients from nine participating centers in China were enrolled into this study and randomly assigned to two treatment groups. For ENI and IFI groups, respectively, the results showed similarity and were as follows: median PFS (20.3 months vs 21.4 months), OS (32.5 months vs 34.9 months), MFS (28.2 months vs 26.0 months), and LRFS (25.0 months vs 26.6 months). In particular, respective OS rates in the ENI and IFI groups were 84.6% and 82.5% after 1 year, 45.1% and 48.7% after 3 years, and 29.8% and 30.7% at 5 years. PFS rates after 1, 3, and 5 years were 58.9%, 34.2%, and 26.9%, respectively, in the ENI arm compared to 64.4%, 30.8%, and 27.7%, respectively, in the IFI arm. Multivariate analysis identified clinical stage and tumor responses as independent predictors of OS. Meanwhile, tumor location, cStage, and tumor response were identified as independent factors influencing PFS. IFI was associated with similar survival as ENI in patients with thoracic ESCC, suggesting that IFI is an acceptable treatment method for thoracic ESCC.
Sections du résumé
BACKGROUND
This study's initial results revealed significant decreases in treatment-related esophagitis and pneumonitis cases in patients with thoracic esophageal squamous cell carcinoma (ESCC) treated with involved-field irradiation (IFI), compared to elective nodal irradiation (ENI). This report outlines the long-term trial results, specifically; overall survival (OS), progression-free survival (PFS), metastasis-free survival (MFS), and locoregional progression-free survival (LRFS).
MATERIALS AND METHODS
Stage II-III thoracic ESCC patients were assigned randomly, in a 1:1 ratio, into either the ENI or IFI arm. Radiation therapy was delivered once a day in 1.8-2.0 Gy fractions to a total dose of 60.0-66.0 Gy to the gross tumor volume and 50.0-54.0 Gy to the clinical target volume. The primary endpoints were acute treatment-related esophagitis and pneumonitis. The results for the primary endpoints were previously published in 2018. In this article, we analyzed the secondary endpoints including PFS, LRFS, MFS, and OS.
RESULTS
Between April 2012 and October 2016, 228 patients from nine participating centers in China were enrolled into this study and randomly assigned to two treatment groups. For ENI and IFI groups, respectively, the results showed similarity and were as follows: median PFS (20.3 months vs 21.4 months), OS (32.5 months vs 34.9 months), MFS (28.2 months vs 26.0 months), and LRFS (25.0 months vs 26.6 months). In particular, respective OS rates in the ENI and IFI groups were 84.6% and 82.5% after 1 year, 45.1% and 48.7% after 3 years, and 29.8% and 30.7% at 5 years. PFS rates after 1, 3, and 5 years were 58.9%, 34.2%, and 26.9%, respectively, in the ENI arm compared to 64.4%, 30.8%, and 27.7%, respectively, in the IFI arm. Multivariate analysis identified clinical stage and tumor responses as independent predictors of OS. Meanwhile, tumor location, cStage, and tumor response were identified as independent factors influencing PFS.
CONCLUSION
IFI was associated with similar survival as ENI in patients with thoracic ESCC, suggesting that IFI is an acceptable treatment method for thoracic ESCC.
Identifiants
pubmed: 32841543
doi: 10.1002/cam4.3409
pmc: PMC7571810
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7460-7468Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Radiat Oncol. 2012 Nov 27;7:200
pubmed: 23186308
Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):353-9
pubmed: 7836089
J Radiat Res. 2018 Sep 1;59(5):604-615
pubmed: 30085197
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Cancer Lett. 2000 Oct 31;159(2):119-25
pubmed: 10996722
Blood. 2009 Jul 16;114(3):589-95
pubmed: 19349616
JAMA. 1999 May 5;281(17):1623-7
pubmed: 10235156
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Radiat Oncol. 2019 Oct 16;14(1):176
pubmed: 31619265
Onco Targets Ther. 2017 Apr 11;10:2087-2095
pubmed: 28442917
Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
Medicine (Baltimore). 2019 Jan;98(3):e14080
pubmed: 30653123
Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):671-7
pubmed: 23773390
Cancer Med. 2020 Oct;9(20):7460-7468
pubmed: 32841543
Radiat Res. 2014 Aug;182(2):123-5
pubmed: 25036983
Radiother Oncol. 2014 Nov;113(2):166-74
pubmed: 25465727
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):446-51
pubmed: 20004527
Radiother Oncol. 2011 Feb;98(2):255-60
pubmed: 21074880
Onkologie. 2011;34(11):599-604
pubmed: 22104156
Clinics (Sao Paulo). 2018 Dec 10;73(suppl 1):e557s
pubmed: 30540123